Sonelokimab (ALX 0761) 是一种由驼源的人源化 IL-17F 抗体、IL-17A/F 抗体和血清白蛋白 VHH 抗体组成的三价双特异性纳米抗体。Sonelokimab 与人血清白蛋白结合后可以延长血浆半衰期。Sonelokimab 可用于类风湿性关节炎和银屑病的研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) is 40.93 kDa.

Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) is 98.70%, determined by SEC-HPLC.

Sonelokimab bound to IL-17F protein, and then rebounded to secondary antibodies (Anti-human-IgG-His-HRP) , and read OD450. As shown in fig, Sonelokimab bound in hu-IL-17F-Fc, and the EC50 was 0.009 nM.

Sonelokimab bound to HSA protein, and then rebounded to secondary antibodies (Anti-human-IgG-His-HRP) , and read OD450. As shown in fig, Sonelokimab bound in hu-HSA-Fc, and the EC50 was 0.022nM.

Co-incubation of NHDF cells with TNF-α and IL-17A protein, then with the addition of Sonelokimab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig 3, Sonelokimab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 2.877 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.